Reported 2 days ago
Amgen has announced concerning results from its clinical trial of the GLP-1 drug MariTide, revealing that over a quarter of participants at the highest dosage stopped due to adverse side effects, raising doubts about its viability. As Eli Lilly and Novo Nordisk continue to dominate the GLP-1 market with approved products, investors might prefer these established companies over Amgen, especially since the obesity drug market is projected to reach $200 billion by 2031.
Source: YAHOO